A woman enrolled in the fingolimod arm of the phase III FREEDOMS II trial developed severe haemorrhagic focal encephalitis.

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1249, 2009-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Campath dosing suspended in phase II trial: cases of severe ITP

By  

Reactions Weekly, Vol. 1, Iss. 1070, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Optimal Designs for Two-Arm, Phase II Clinical Trial Design with Multiple Constraints

By Mayo Matthew  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 106-124

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial

By Galanis Evanthia   Buckner Jan   Maurer Matthew   Reid Joel   Kuffel Mary   Ames Matthew   Scheithauer Bernd   Hammack Julie   Pipoly George   Kuross Steven  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 495-503

Springer Publishing Company

Access to resources Recommend Favorite

Between-Arm Comparisons in Randomized Phase II Trials

By Jung Sin-Ho   George Stephen  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 456-468

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite